|Reference : Nanobodies as structural probes to investigate the mechanism of fibril formation by t...|
|Scientific congresses and symposiums : Poster|
|Life sciences : Biochemistry, biophysics & molecular biology|
|Nanobodies as structural probes to investigate the mechanism of fibril formation by the amyloidogenic variants of human lysozyme|
|Dumont, Janice [Université de Liège - ULg > Département des sciences de la vie > Enzymologie et repliement des protéines >]|
|Pardon, Els [Vrije Universiteit Brussels - VUB > Department Ultrastructure > > >]|
|Aumont-Nicaise, Magalie [ > > ]|
|Desmadril, Michel [ > > ]|
|Menzer, Linda [Université de Liège - ULg > > > 2e an. master bioch. & biol. moléc. & cell., fin. appr.]|
|Wyns, Lode [ > > ]|
|steyaert, Jan [ > > ]|
|Dobson, Christopher [ > > ]|
|Dumoulin, Mireille [Université de Liège - ULg > Département des sciences de la vie > Enzymologie et repliement des protéines >]|
|Amyloid Fibrils, Prions and Precursors: Molecules for Targeted Intervention|
|25-28 August 2011|
|[en] Amyloid Fibril ; Nanobodies ; Lysozyme|
|[en] Six variants of human lysozyme (single-point mutations I56T, F57I, W64R, D67H and double mutations F57I/T70N, W112R/T70N) are associated with a hereditary non-neuropathic systemic amyloidose. These proteins form extracellular amyloid fibrils that deposit in a wide range of tissues and organs such as liver, spleen and kidneys where they cause damages . It was shown that the D67H and I56T mutations cause a loss in stability and more particularly a loss of global cooperativity of protein . Consequently, under physiologically relevant conditions, these variants can transiently populate a partially unfolded state in which the beta-domain and the C-helix are cooperatively unfolded while the rest of the protein remains native like . The formation of intermolecular interactions between the regions that are unfolded in this intermediate state is likely to be a fundamental trigger of the aggregation process that ultimately leads to the formation and deposition of fibrils in tissues. We have also shown that the binding of three variable domain of camelid antibodies or (VHHs) - raised against the wild type human lysozyme inhibit in vitro the formation of amyloid fibrils by the lysozyme variants. These three VHHs bind on different regions of lysozyme and act as amyloid fibrils inhibitor through different mechanisms [2, 3, and unpublished results].
In the present work, sixteen new VHHs specific of human lysozyme have been generated. Competition experiments have shown that they bind to five non overlapping epitopes. We have demonstrated that five of these new VHHs are able to bind lysozyme in conditions used for amyloid fibril formation, and interestingly two of them recognize two epitopes that are different from those of the three VHHs previously characterized [2, 3, and unpublished results]. The effects of these new VHHs on the properties of lysozyme variants such as activity, stability, cooperativity and aggregation will be discussed.
There is no file associated with this reference.
All documents in ORBi are protected by a user license.